Rapport Therapeutics, Inc.
RAPP
$11.49
$0.110.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -19.98M | -17.54M | -18.12M | -22.67M | -13.52M |
| Total Depreciation and Amortization | 260.00K | 219.00K | 208.00K | 152.00K | 53.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.93M | 1.38M | 1.68M | 8.06M | 1.17M |
| Change in Net Operating Assets | 1.34M | -477.00K | -123.00K | -3.16M | 1.94M |
| Cash from Operations | -14.45M | -16.42M | -16.35M | -17.62M | -10.36M |
| Capital Expenditure | -226.00K | -140.00K | -967.00K | -1.07M | -1.44M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 32.16M | -52.90M | -106.14M | -40.85M | -77.22M |
| Cash from Investing | 31.93M | -53.04M | -107.10M | -41.93M | -78.66M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.00K | -- | 159.10M | -- | 0.00 |
| Repurchase of Common Stock | -- | -1.39M | -- | -- | 0.00 |
| Issuance of Preferred Stock | 0.00 | 0.00 | -- | 63.94M | -- |
| Repurchase of Preferred Stock | -- | -- | -29.00K | -- | -6.00K |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 283.00K | -283.00K | -134.00K |
| Cash from Financing | 7.00K | -1.39M | 159.35M | 63.66M | -140.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 17.49M | -70.85M | 35.90M | 4.12M | -89.16M |